Achieve Life Sciences details cytisinicline CRL response and resubmission plan for Q2 2026

Achieve Life Sciences reported second quarter 2026 results on August 11, 2026, detailing its response to the Complete Response Letter it received from the FDA on June 20, 2026 for the cytisinicline NDA. The company said it had anticipated this outcome as of April 2026.¹ The CRL cited outstanding cGMP observations from an inspection of Achieve's prior third-party manufacturing facility, which received an Official Action Indicated classification, along with final product labeling that was not completed by the FDA's action date.¹ The FDA identified no deficiencies related to the clinical efficacy or safety of cytisinicline.¹

To address the manufacturing issue, Achieve announced the transition of finished drug product manufacturing to U.S.-based Adare Pharma Solutions, completing analytical method technology transfer, manufacturing its first engineering batch, and fully qualifying testing procedures at Adare's facility.¹ The company intends to resubmit its NDA naming Adare as the finished drug product manufacturer for commercial supply in the fourth quarter of 2026, and anticipates potential FDA approval in the first half of 2027, with U.S. commercial launch to follow.¹

On the clinical side, Achieve presented 52-week safety data from the ORCA-OL study at the ATS 2026 Annual Meeting, completing the clinical evidence package supporting the NDA; among 475 participants dosed for up to 52 weeks, no new safety signals were identified by the independent Data Safety Monitoring Committee.¹ Separately, an ASCO 2026 presentation analyzing ORCA-2 and ORCA-3 Phase 3 trials in participants with a history of cancer showed cytisinicline was well tolerated with numerically higher abstinence rates than placebo, 24.4% versus 15.8% at 12 weeks.¹

On financing, Achieve closed a private placement of up to $354 million, comprising $180 million upfront and up to $174 million from milestone-based warrants exercisable before and up to 20 trading days after FDA approval, with proceeds expected to fund the ORCA-V2 Phase 3 trial, commercialization, and working capital.¹ As of June 30, 2026, cash, cash equivalents, and marketable securities totaled $187.3 million.¹